Heron Therapeutics (HRTX) Amortizatization of Intangibles (2011 - 2026)
Heron Therapeutics' (HRTX) quarterly Amortizatization of Intangibles came in at $144000.0 in Q1 2026, down 48.75% YoY from $281000.0 in Q1 2025, and up 61.8% on a QoQ basis from $89000.0 in Q4 2025.
Heron Therapeutics (HRTX) Amortizatization of Intangibles (2011 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 16 years of Amortizatization of Intangibles data on file, last reported at $144000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 48.75% year-over-year to $144000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $433000.0 (down 80.5% YoY) and the FY2025 annual result came in at $739000.0, down 65.52% from the prior year.
- Amortizatization of Intangibles grew to $144000.0 in Q1 2026, from $89000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.6 million in Q4 2024 to a low of -$1.0 million in Q4 2023.
- A 5-year average of $195375.0 and a median of $172000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 555.77% in 2023, down 3472.73% in 2023.
- Tracing HRTX's Amortizatization of Intangibles over 5 years: stood at $574000.0 in 2022, then plunged by 281.18% to -$1.0 million in 2023, then surged by 257.6% to $1.6 million in 2024, then plunged by 94.57% to $89000.0 in 2025, then surged by 61.8% to $144000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $144000.0 (Q1 2026), $89000.0 (Q4 2025), and $200000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Heron Therapeutics | 59.96 Mn | 17.29 Mn | 26.09 Mn | 200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 144,000.00 |
| Mar 31, 2026 | 144,000.00 |
| Dec 31, 2025 | 89,000.00 |
| Dec 31, 2025 | 89,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 281,000.00 |
| Mar 31, 2025 | 281,000.00 |
| Dec 31, 2024 | 1.64 Mn |
| Dec 31, 2024 | 1.64 Mn |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 638,000.00 |
| Mar 31, 2024 | 638,000.00 |
| Dec 31, 2023 | -1.04 Mn |
| Dec 31, 2023 | -1.04 Mn |